Selank

research/region-specificCognition/Mood

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeAnxiety / Cognition

MechanismNeuropeptide analog studied for anxiolytic effects

EffectsNeuropeptide analog studied for anxiolytic effects

DosingNo human dose established.

Bottom linePopular in research/compounding; human safety/benefit not well-established.

Protocols · as published1 sourced

Community protocol — not clinically establishedCommunity guide

RouteSubcutaneous (community only); intranasal

FrequencySC once daily; intranasal split 2-3x daily

StartingSC 250-300 mcg once daily, weeks 1-2

EscalationSC 400-500 mcg weeks 3-4 if tolerated

TargetSC 250-500 mcg daily. Intranasal 600-2,700 mcg/day split into 2-3 administrations.

CycleSC 4 weeks on / 4 weeks off. Intranasal 14-21 days with a 1-3 week washout.

Registered in Russia as nasal drops; not approved in the US or EU. The guide says SC evidence "comes from community practice".

Sourcepeptidedosingprotocols.com ↗

Batches on filenone

No tested batches on file.

Read with10

VIP Semaglutide Tirzepatide Liraglutide Exenatide Dulaglutide Pramlintide Cagrilintide Retatrutide Leptin / Metreleptin

Cautions & interactions

Regulatory status varies; avoid unsupervised use

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.